CRYSTAL FORMS III, IV, V, AND NOVEL AMORPHOUS FORM OF CLOPIDOGREL HYDROGENSULFATE, PROCESSES FOR THEIR PREPARATION, PROCESSES FOR THE PREPARATION OF FORM I, COMPOSITIONS CONTAINING THE NEW FORMS AND METHODS OF ADMINISTERING THE NEW FORMS
February 12, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesThieno [3,2-c] pyridine derivatives and their therapeutic application Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it Process for the preparation of -bromo-phenylacetic acids 2-thienylglycidic derivative, process for its preparation and its use as synthesis intermediate Process for the preparation of an n-phenylacetic derivative of tetrahydrothieno(3,2-c)pyridine and its chemical intermediate Method for the secondary prevention of ischemic events Method for preparing 2-thienylethylamine derivatives Process for the preparation of a pharmacologically active substance Intermediates and process for the preparation thereof Intermediates and process for the preparation thereof InventorsAssigneeApplicationNo. 10074409 filed on 02/12/2002US Classes:514/301, Ring sulfur in the bicyclo ring system546/114Ring sulfur in the bicyclo ring systemExaminersPrimary: Rotman, Alan L.Assistant: Covington, Raymond Attorney, Agent or FirmForeign Patent References
International ClassesA61K 3144C07D47102 AbstractThe present invention provides new crystalline Forms III, IV and V of clopidogrel hydrogensulfate and the amorphous form of clopidogrel hydrogensulfate, as well as their pharmaceutical compositions, and method of treatments with such compositions. The present invention also provides novel processes for preparation of clopidogrel hydrogensulfate Form I, Form III, Form IV, Form V and the amorphous form. The present invention further provides a novel process where the amorphous form is converted to Form I by contacting Form I with an ether.Other References
|
| ||||||||||||||
